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Abstract
Obesity increases the risk of low 25-hydroxyvitamin D (25(OH)D) concentrations and gestational diabetes (GDM). We
explored whether the association between GDM and change in 25(OH)D concentrations measured in the ﬁrst (7–18 wk) and
second (20–27 wk) trimesters of pregnancy is dependent on maternal BMI. The study was a prospective study of 219 women
with BMI of ≥30 kg/m2, a history of GDM, or both. The participants were stratiﬁed by ﬁrst-trimester BMI: BMI of <25.0,
25.0–29.9, 30.0–34.9, and ≥35 kg/m2. In the BMI group ≥35 kg/m2, those who did not develop GDM during the follow-up
showed higher increase in serum 25(OH)D concentrations compared with women who developed GDM (43.2 vs. 11.5%; P
< 0.001). No associations between 25(OH)D concentrations and GDM were observed in other BMI groups. These ﬁndings
give an important aspect of the role of maternal body size in the association between vitamin D and GDM in high-risk
women.
Introduction
Gestational diabetes (GDM) refers to hyperglycemia ﬁrst
recognized in pregnancy [1]. Major risk factors for GDM
include obesity and a history of GDM [2].
Observational studies have linked low 25-
hydroxyvitamin D (25(OH)D) concentrations during preg-
nancy with a higher risk of GDM [3]. Also, randomized
studies have reported improved maternal glucose–insulin
metabolism after vitamin D supplementation [4]. However,
the evidence for vitamin D-glucose metabolism associations
is still contradictory [5].
Obesity increases the risk of both low 25(OH)D con-
centrations [6] and GDM [1]. In the studies on vitamin D
and GDM, body mass index (BMI) has usually been used
only for adjustments whereas further examination of the
role of BMI is limited.
The objective of the present study was to explore pro-
spectively whether the association of change in maternal 25
(OH)D concentrations and GDM is dependent on maternal
body size in high-risk women. To our knowledge, no such
study has been published.
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Subjects and methods
The subjects were a part of the Finnish gestational diabetes
prevention study (RADIEL), which is a lifestyle intervention
study conducted between 2008 and 2014 among high-risk
women. The study was performed according to the guide-
lines laid down in the Declaration of Helsinki. All proce-
dures were approved by the Ethics Committees of Helsinki
Table 1 Baseline characteristics
according to BMI in the ﬁrst
trimester of pregnancy (n= 219
unless otherwise speciﬁed)
BMI (kg/m2)
<25.0 25.0-29.9a 30.0-34.9 ≥35.0
(n= 43) (n= 34) (n= 84) (n= 58) Pb
Age (years) 33.0 (3.9) 33.2 (3.6) 31.7 (4.7) 31.4 (4.3) 0.052
Gestational age (weeks) 12.7 (1.7) 13.1 (2.1) 13.3 (1.7) 13.4 (2.1) 0.064
Educational attainment (n 216), n (%) 0.027
No education/vocational school 14 (33) 13 (39) 34 (41) 27 (47)
Vocational degree 11 (26) 7 (21) 27 (33) 19 (33)
Academic degree 18 (42) 13 (39) 21 (26) 12 (21)
Previous deliveries, n (%) 43 (100) 32 (94) 42 (50) 24 (41) <0.001
Prior GDM, n (%) 43 (100) 30 (88) 15 (18) 8 (14) <0.001
Blood pressure (mmHg) (n 215)
Systolic 115 (10) 118 (13) 123 (14) 127 (12) <0.001
Diastolic 72 (8) 73 (7) 79 (9) 81 (8) <0.001
Total cholesterol (mmol/l) (n 201) 4.79 (0.80) 4.87 (1.06) 4.96 (0.90) 5.01 (0.76) 0.157
HDL cholesterol (mmol/l) (n 201) 1.89 (0.25) 1.68 (0.32) 1.75 (0.33) 1.67 (0.28) 0.002
LDL cholesterol (mmol/l) (n 201) 2.62 (0.68) 2.79 (0.88) 2.82 (0.83) 2.91 (0.58) 0.035
Total triglycerides (mmol/l) (n 200) 1.02 (0.37) 1.30 (0.64) 1.38 (0.51) 1.51 (0.92) <0.001
Fasting glucose (mmol/l) 4.79 (0.32) 4.97 (0.21) 4.85 (0.24) 4.90 (0.22) 0.559
1-h glucose (mmol/l) 7.18 (1.55) 7.31 (1.53) 6.80 (1.34) 7.09 (1.07) 0.415
2-h glucose (mmol/l) 5.90 (1.25) 5.78 (1.03) 5.76 (1.03) 5.90 (1.04) 0.600
HbA1c (%) (n 190) 5.26 (0.23) 5.24 (0.24) 5.22 (0.32) 5.23 (0.23) 0.662
Fasting insulin (mU/l) (n 200) 5.47 (4.46) 5.79 (2.74) 9.78 (9.41) 10.85 (4.46) <0.001
HOMA-IRc (n 190) 1.19 (0.97) 1.26 (0.67) 2.10 (2.08) 2.38 (1.04) <0.001
hs-CRP (mg/l) (n 216) 4.09 (4.50) 5.33 (4.79) 6.82 (4.36) 10.26 (5.67) <0.001
HFII score (n 193) 11.1 (2.7) 10.2 (3.0) 9.9 (2.6) 10.1 (2.9) 0.112
25(OH)D (nmol/l) 74 (23) 73 (32) 64 (24) 57 (22) <0.001
Physical activity (min/week) (n 200) 0.432
Median 90 85 60 60
IQR 45, 150 30, 130 30, 120 43, 120
Current smoking, n (%) 1 (2) 2 (6) 1 (1) 3 (5) 0.723
Vitamin D deﬁciency (<50 nmol/l), n (%) 5 (12) 9 (26) 26 (31) 25 (43) 0.001
Season of blood collection, n (%) 0.455
Spring 12 (28) 8 (24) 23 (27) 16 (27)
Summer 9 (21) 11 (32) 18 (21) 8 (14)
Fall 14 (32) 7 (21) 19 (23) 19 (33)
Winter 8 (19) 8 (23) 24 (29) 15 (26)
The data are given as mean (s.d.) for continuous variables and as n (percentages) for categorical variables
GDM gestational diabetes, HOMA-IR homeostatic model assessment of insulin resistance, hs-CRP high-
sensitivity C-reactive protein, 25(OH)D 25-hydroxyvitamin D, HbA1c glycated hemoglobin, HFII Healthy
Food Intake Index, IQR interquartile range
aIn the BMI group 25.0-29.9 kg/m2, 12% (n= 4) had BMI of ≥30 kg/m2 before pregnancy but lost weight
until the ﬁrst trimester of pregnancy. Thus, these women were included in the BMI group 25.0–29.9 kg/m2
bP values are for linearity across BMI groups by using ANOVA or Cochran–Armitage test for trend
cCalculated as [fasting insulin (mU/l) × fasting glucose (mmol/l))/22.5]
Vitamin D and gestational diabetes 461
University Central Hospital and South-Karelia Central
Hospital. All participants provided written informed consent.
The inclusion criteria were age of ≥18 years, and a his-
tory of GDM or pre-pregnancy BMI of ≥30 kg/m2, or both.
Out of the original 357 women, 219 were eligible for the
current study.
The criteria for GDM diagnosis was at least one patho-
logical glucose value in a 2-h 75 g oral glucose tolerance
test (OGTT); fasting glucose ≥5.3 mmol/l, 1-h glucose
≥10.0 mmol/l, and/or 2-h glucose ≥8.6 mmol/l [7]. The
OGTT was conducted in the ﬁrst (5–20 wk in the current
study) and second (22–30 wk) trimester.
Serum 25(OH)D concentrations were measured in the
ﬁrst (7–18 wk) and second (20–27 wk) trimester.
Stata 13.1, StataCorp LP (College Station, TX, USA) was
used in the analyses. The women were stratiﬁed into groups
according to ﬁrst-trimester BMI; BMI of <25, 25.0–29.9,
30.0–34.9, and ≥35 kg/m2. Statistical comparison between
groups for GDM was made by the analysis of variance
(ANOVA). ANOVA and Cochran–Armitage test were used
to evaluate statistical signiﬁcance for hypotheses of linearity.
Correlations were calculated between percentage change in
25(OH)D concentrations from the ﬁrst to the second trime-
ster and area under the curve (AUC) of the diagnostic OGTT
in the second trimester. Correlation coefﬁcients were cal-
culated by the Pearson method. The total and incremental
AUCs for OGTT (fasting, 1-h, and 2-h glucose values) were
determined by the trapezoidal method. Bootstrap-type
test was performed if the assumptions were violated (e.g.,
non-normality). A P value of <0.05 was considered
signiﬁcant.
Adjustments were performed for potential confounding
factors; baseline 25(OH)D concentrations, season, inter-
vention group, and change in diet quality, physical activity,
and weight from the ﬁrst to the second trimester.
The prevalence of previous GDM was 100% (n= 43)
and 88% (n= 30) in the BMI groups <25.0 and
25.0–29.9 kg/m2, respectively. Thus, the adjustments for
previous GDM were performed only in the BMI groups
30.0–34.9 and ≥35 kg/m2. In the BMI group 25.0–29.9 kg/
m2, four women had pre-pregnancy BMI of ≥30 kg/m2 but
lost weight until the ﬁrst trimester.
More detailed description of the exclusion criteria and
data collection is available in the Supplementary
Information.
Results
Baseline characteristics are presented in Table 1.
The overall GDM incidence was 17% (n= 37).
According to BMI, the incidence was 37% (n= 16) in the
BMI group <25 kg/m2, 24% (n= 8) in the BMI group 25.0-
29.9 kg/m2, 7% (n= 6) in the BMI group 30.0-34.9 kg/m2,
and 12% (n= 7) in the BMI group ≥35 kg/m2 (P < 0.001).
In the BMI group ≥35 kg/m2, the increase in 25(OH)D
concentrations was signiﬁcantly higher among women not
developing GDM compared with women developing GDM
(43.2 vs. 11.5%; P < 0.001) (Fig. 1). The difference
remained after adjustment for the confounders (P < 0.01).
Similarly, the change in 25(OH)D concentrations was
inversely correlated with AUC of the OGTT(0-2h) in the
second trimester only among women in the highest BMI
group (Supplementary Fig. S1).
Changes in 25(OH)D concentrations, weight, and life-
style are available at Supplementary Table S1.
Discussion
These ﬁndings suggest that a greater increase in 25(OH)D
concentrations is associated with lower GDM risk in preg-
nant women with BMI of ≥35 kg/m2 but not among women
with lower BMI. The ﬁndings were further supported by
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Fig. 1 Percentage change in serum 25(OH)D concentrations from the
ﬁrst to the second trimester in different GDM groups according to ﬁrst-
trimester BMI. The increase in serum 25(OH)D concentrations was
signiﬁcantly higher among women not developing GDM (GDM-)
compared to women developing GDM (GDM+) in the BMI group
≥35 kg/m2 (P < 0.001). GDM gestational diabetes, 25(OH)D 25-
hydroxyvitamin D
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that the change in 25(OH)D concentrations was inversely
correlated with AUC of the diagnostic OGTT.
The current results are similar to ﬁndings from obser-
vational studies suggesting that 25(OH)D concentrations
may have more inﬂuence on glucose–insulin metabolism
among overweight and obese individuals compared with
normal-weight individuals [8, 9].
Studies on overweight and obese adults have shown
improved 25(OH)D concentrations after vitamin D supple-
mentation but no changes in glucose and insulin metabolism
[10]. Reasons for this might include too low vitamin D dose
or examining the obese and severely obese participants as
one group. However, as suggested by the current ﬁndings,
improved 25(OH)D concentrations may have more bene-
ﬁcial inﬂuence in severely obese than in obese individuals.
More adverse metabolic proﬁle in the BMI group ≥35 kg/
m2 compared with other BMI groups may partly explain the
current ﬁndings. Additionally, the GDM incidence was
highest among women with the lowest BMI and metabolic
risk status, which most likely results from the inclusion
criteria; all women with BMI of <30 kg/m2 had a history of
GDM. Previous GDM increases the risk for future GDM
and thus may have attenuated the results among these
women.
These ﬁndings provide an important aspect of the com-
plex association between body size, 25(OH)D concentra-
tions, and risk of GDM. Large randomized controlled trials
are required to conclude if maternal BMI inﬂuences the
association of vitamin D with GDM in high-risk population.
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